VARIOUS R/R PCNSL Treatment Options1,2
But No
Clear Choice

After initial response to first-line therapy, many patients with primary central nervous system lymphoma (PCNSL) will experience refractory or relapsed disease—and FDA-approved therapies are limited.1-3

Understanding R/R PCNSL

No accepted standard of care

There is no consensus on the optimal treatment strategy.3

Current Treatment Challenges
Future Outlook

*May include targeted agents, immunomodulatory agents, or other monotherapy/combination regimens.2

†Also a type of chemotherapy.

Not all drugs within the presented classes are used in the treatment of R/R PCNSL.

ASCT=autologous stem cell transplantation; BTKi=Bruton tyrosine kinase inhibitor; FDA=Food and Drug Administration; IMiDs=immunomodulatory drugs; mAbs=monoclonal antibodies; R/R PCNSL=relapsing or refractory primary central nervous system lymphoma; WBRT=whole brain radiation therapy.

References: 1. Langner-Lemercier S, Houillier C, Soussain C, et al. Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network. Neuro Oncol. 2016;18(9):1297-1303. doi:10.1093/neuonc/now033 2. Ambady P, Doolittle ND, Fox CP. Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. Ann Lymphoma. 2021;5:23. doi:10.21037/aol-21-20 3. Mendez JS, Grommes C. Treatment of primary central nervous system lymphoma: from chemotherapy to small molecules. Am Soc Clin Oncol Educ Book. 2018;38:604-615. doi:10.1200/EDBK_200829 4. Tao K, Wang X, Tian X. Relapsed primary central nervous system lymphoma: current advances. Front Oncol. 2021;11:649789. doi:10.3389/fonc.2021.649789